An Open-Label, Long-Term Study to Assess the Safety and Efficacy of YM178 in Symptomatic Overactive Bladder Patients.

Trial Profile

An Open-Label, Long-Term Study to Assess the Safety and Efficacy of YM178 in Symptomatic Overactive Bladder Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2013

At a glance

  • Drugs Mirabegron (Primary)
  • Indications Overactive bladder
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top